Rosetta Genomics Ltd
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LU… Read more
Rosetta Genomics Ltd (ROSGQ) - Net Assets
Latest net assets as of June 2017: $1.10 Million USD
Based on the latest financial reports, Rosetta Genomics Ltd (ROSGQ) has net assets worth $1.10 Million USD as of June 2017.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.21 Million) and total liabilities ($5.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.10 Million |
| % of Total Assets | 17.71% |
| Annual Growth Rate | 10.79% |
| 5-Year Change | -85.71% |
| 10-Year Change | -81.29% |
| Growth Volatility | 100.69 |
Rosetta Genomics Ltd - Net Assets Trend (2004–2016)
This chart illustrates how Rosetta Genomics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rosetta Genomics Ltd (2004–2016)
The table below shows the annual net assets of Rosetta Genomics Ltd from 2004 to 2016.
| Year | Net Assets | Change |
|---|---|---|
| 2016-12-31 | $4.42 Million | -77.49% |
| 2015-12-31 | $19.62 Million | +30.24% |
| 2014-12-31 | $15.06 Million | -36.25% |
| 2013-12-31 | $23.63 Million | -23.52% |
| 2012-12-31 | $30.90 Million | +8779.78% |
| 2011-12-31 | $-356.00K | +43.49% |
| 2010-12-31 | $-630.00K | -109.21% |
| 2009-12-31 | $6.84 Million | -57.50% |
| 2008-12-31 | $16.10 Million | -31.79% |
| 2007-12-31 | $23.61 Million | +112.68% |
| 2006-12-31 | $11.10 Million | +577.79% |
| 2005-12-31 | $-2.32 Million | -279.94% |
| 2004-12-31 | $1.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rosetta Genomics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14912200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2016)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.44 Million | 77.93% |
| Other Components | $157.48 Million | 3565.27% |
| Total Equity | $4.42 Million | 100.00% |
Rosetta Genomics Ltd Competitors by Market Cap
The table below lists competitors of Rosetta Genomics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NIGERIA ENAMELWARE PLC
XNSA:ENAMELWA
|
$217.79 |
|
INDUSTRIAL & MEDICAL GASES NIGERIA PLC
XNSA:IMG
|
$218.37 |
|
EZTD Inc
PINK:EZTD
|
$218.39 |
|
Spod Lithium Corp.
OTCQB:SPODF
|
$218.68 |
|
Browar Czarnkow SA
WAR:BRO
|
$217.10 |
|
First Fidelity Leasing Modaraba
KAR:FFLM
|
$216.37 |
|
Abdullah Shah Ghazi Sugar Mills Ltd
KAR:AGSML
|
$216.37 |
|
STI Education Systems Holdings Inc
PSE:STI
|
$216.30 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rosetta Genomics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2015 to 2016, total equity changed from 19,620,000 to 4,417,000, a change of -15,203,000 (-77.5%).
- Net loss of 16,233,000 reduced equity.
- Other factors increased equity by 1,030,000.
Equity Change Factors (2015 to 2016)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.23 Million | -367.51% |
| Other Changes | $1.03 Million | +23.32% |
| Total Change | $- | -77.49% |
Book Value vs Market Value Analysis
This analysis compares Rosetta Genomics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $377.49 | $0.00 | x |
| 2005-12-31 | $-670.42 | $0.00 | x |
| 2006-12-31 | $3131.39 | $0.00 | x |
| 2007-12-31 | $1525.36 | $0.00 | x |
| 2008-12-31 | $962.98 | $0.00 | x |
| 2009-12-31 | $363.74 | $0.00 | x |
| 2010-12-31 | $-60.89 | $0.00 | x |
| 2011-12-31 | $-8.42 | $0.00 | x |
| 2012-12-31 | $83.35 | $0.00 | x |
| 2013-12-31 | $29.56 | $0.00 | x |
| 2014-12-31 | $16.08 | $0.00 | x |
| 2015-12-31 | $15.60 | $0.00 | x |
| 2016-12-31 | $2.53 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rosetta Genomics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -367.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -175.80%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 2.71x
- Recent ROE (-367.51%) is below the historical average (-100.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -230.98% | 0.00% | 0.00x | 1.61x | $-3.11 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.61 Million |
| 2006 | -68.54% | 0.00% | 0.00x | 1.19x | $-8.72 Million |
| 2007 | -62.11% | 0.00% | 0.00x | 1.10x | $-17.02 Million |
| 2008 | -58.78% | -626.27% | 0.07x | 1.26x | $-11.07 Million |
| 2009 | -241.23% | -11003.33% | 0.01x | 1.86x | $-17.19 Million |
| 2010 | 0.00% | -5288.53% | 0.05x | 0.00x | $-14.61 Million |
| 2011 | 0.00% | -8572.82% | 0.05x | 0.00x | $-8.79 Million |
| 2012 | -33.84% | -5202.49% | 0.01x | 1.05x | $-13.55 Million |
| 2013 | -54.57% | -3184.44% | 0.02x | 1.10x | $-15.26 Million |
| 2014 | -96.42% | -1094.65% | 0.08x | 1.15x | $-16.03 Million |
| 2015 | -88.40% | -209.78% | 0.37x | 1.14x | $-19.31 Million |
| 2016 | -367.51% | -175.80% | 0.77x | 2.71x | $-16.67 Million |
Industry Comparison
This section compares Rosetta Genomics Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rosetta Genomics Ltd (ROSGQ) | $1.10 Million | -230.98% | 4.65x | $217.71 |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |